FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025.
FY 2025 key results1
Group performance2: Double-digit revenue growth and positive adjusted operating cash flow
- Revenue of US$803.8 million,...
Read more: FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment






